Introduction Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a condition that causes progressive renal function decline. Preclinical data suggest the presence of a profound metabolic derangement in ADPKD. Cystic cells shift their energy metabolism from oxidative phosphorylation to aerobic glycolysis, show inhibition of fatty acid oxidation and become glutamine and arginine dependent. Recent preclinical experiences have suggested beneficial effect in terms of reduction of cystic size, interstitial fibrosis and disease progression, targeting these deregulated metabolic pathways by ketosis induction. The dietetic approach to ADPKD, because of low cost and absence of toxicity, represents an interesting therapeutic strategy. Methods and analysis The protocol describes a phase II clinical trial that will evaluate the effect on Total Kidney Volume, safety and tolerability of a ketogenic diet in a selected ADPKD population. The trial will have, as secondary objective, the evaluation of the ability of the ketogenic diet to slow down the renal function decline. This will be a 12-month randomized, parallel group, two arm, superiority trial with 1:1 allocation to evaluate the efficacy of a Modified Atkins Diet protocol compared to a balanced normocaloric diet on 90 ADPKD patients. Dissemination The study results will be released to the patients and the medical community.

GREASE II. A phase II randomized, 12-month, parallel-group, superiority study to evaluate the efficacy of a Modified Atkins Diet in Autosomal Dominant Polycystic Kidney Disease patients / Testa, Francesca; Marchiò, Maddalena; D’Amico, Roberto; Giovanella, Silvia; Ligabue, Giulia; Fontana, Francesco; Alfano, Gaetano; Cappelli, Gianni; Biagini, Giuseppe; Magistroni, Riccardo. - In: PHARMANUTRITION. - ISSN 2213-4344. - 13:(2020), pp. 1-11. [10.1016/j.phanu.2020.100206]

GREASE II. A phase II randomized, 12-month, parallel-group, superiority study to evaluate the efficacy of a Modified Atkins Diet in Autosomal Dominant Polycystic Kidney Disease patients

Testa, Francesca;Marchiò, Maddalena;D’Amico, Roberto;Giovanella, Silvia;Ligabue, Giulia;Fontana, Francesco;Alfano, Gaetano;Cappelli, Gianni;Biagini, Giuseppe;Magistroni, Riccardo
2020

Abstract

Introduction Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a condition that causes progressive renal function decline. Preclinical data suggest the presence of a profound metabolic derangement in ADPKD. Cystic cells shift their energy metabolism from oxidative phosphorylation to aerobic glycolysis, show inhibition of fatty acid oxidation and become glutamine and arginine dependent. Recent preclinical experiences have suggested beneficial effect in terms of reduction of cystic size, interstitial fibrosis and disease progression, targeting these deregulated metabolic pathways by ketosis induction. The dietetic approach to ADPKD, because of low cost and absence of toxicity, represents an interesting therapeutic strategy. Methods and analysis The protocol describes a phase II clinical trial that will evaluate the effect on Total Kidney Volume, safety and tolerability of a ketogenic diet in a selected ADPKD population. The trial will have, as secondary objective, the evaluation of the ability of the ketogenic diet to slow down the renal function decline. This will be a 12-month randomized, parallel group, two arm, superiority trial with 1:1 allocation to evaluate the efficacy of a Modified Atkins Diet protocol compared to a balanced normocaloric diet on 90 ADPKD patients. Dissemination The study results will be released to the patients and the medical community.
2020
13
1
11
GREASE II. A phase II randomized, 12-month, parallel-group, superiority study to evaluate the efficacy of a Modified Atkins Diet in Autosomal Dominant Polycystic Kidney Disease patients / Testa, Francesca; Marchiò, Maddalena; D’Amico, Roberto; Giovanella, Silvia; Ligabue, Giulia; Fontana, Francesco; Alfano, Gaetano; Cappelli, Gianni; Biagini, Giuseppe; Magistroni, Riccardo. - In: PHARMANUTRITION. - ISSN 2213-4344. - 13:(2020), pp. 1-11. [10.1016/j.phanu.2020.100206]
Testa, Francesca; Marchiò, Maddalena; D’Amico, Roberto; Giovanella, Silvia; Ligabue, Giulia; Fontana, Francesco; Alfano, Gaetano; Cappelli, Gianni; Bi...espandi
File in questo prodotto:
File Dimensione Formato  
Pharmanutrition Grease II.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 221.79 kB
Formato Adobe PDF
221.79 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1204994
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 14
social impact